Hidradenitis suppurativa successfully treated with adalimumab

Aim: To discuss the new beneficial effect of adalimumab in the management of hidradenitis suppurativa(HS).Case: We report a 25-year-old arabic female with a 14-year history with long-standing poorly controlled active hidradenitis suppurativa who was successfully treated with adalimumab.Discussion: Hidradenitis suppurativa is a skin disorder characterized by the formation of multiple cysts, abscesses and sinus tracts in apocrine gland-bearing areas. The aetiology and pathogenesis of HS are unknown. Current medical and surgical therapies are only minimally effective at treating the disease. The biologic agent Adalimumab is a new promising agent for the treatment of HS.Conclusion: The biologic agent adalimumab is an effective treatment for HS